Future Oncology · 2021 · 20 citations · 15 references
MedicineOncologyChemotherapyMetastasisTumor ProgressionCancer ImmunotherapyCancer ProgressionMalignant NeoplasmsMerkel Cell CarcinomaMetastatic Cancer ManagementTherapy Response AssessmentMedical Chart ReviewMerkel Cell Carcinoma ImmunotherapyMerkel Cell Carcinoma TherapyOncologic Outcomes AssessmentPivotal Study DesignTumor Response Evaluation
Aim: To assess clinical outcomes in patients with locally advanced (la) or metastatic (m) Merkel cell carcinoma (MCC) initiating first-line (1L) avelumab in a USA community oncology setting. Materials & methods: Adults with laMCC or mMCC initiating 1L avelumab were identified from The US Oncology Network electronic health record database and chart review. Results: Median overall survival and progression-free survival were not reached in laMCC (n = 9) vs 20.2 and 10.0 months in mMCC (n = 19); response rates were similar (66.7% vs 63.2%). Conclusion: This is the first study to show clinical benefit in patients with laMCC receiving 1L avelumab in a US real-world setting. Response rates in patients with mMCC were consistent with pivotal trials.
15
Howard L. Kaufman, Jeffery S. Russell, Omid Hamid et al. · Journal for ImmunoTherapy of Cancer · 2018 · 330 citations · Full text
Medicine, Oncology, Pharmacology +17